Main Brain Stimulation Techniques (partial listing) A Review of the Science and Practical Applications of TMS. Impact of Persistent Depression
|
|
- Shawn Ford
- 5 years ago
- Views:
Transcription
1 Main Brain Stimulation Techniques (partial listing) A Review of the Science and Practical Applications of TMS Jon W. Draud, MS, MD Clinical Professor of Psychiatry University of Tennessee College of Medicine Memphis, Tennessee Medical Director of Psychiatry Pain Management Group Trust Point Psychiatric Hospital St. Thomas Rutherford Hospital Medical Director and Principal Draud Sudbury Psychiatric Solutions Private Practice, Adult and Adolescent Psychiatry Nashville, Tennessee FDA Approved Not FDA Approved ECT (electroconvulsive therapy) FEAST (focal electrically administered seizure therapy) rtms (repetitive TMS) Brainsway, Magstim, Neuronetics, Neuralieve, Neostim, Neosync DBS (deep brain stimulation) Parkinson s disease RST (responsive stimulation therapy) Epidural cortical stimulation VNS (vagus nerve stimulation) Epilepsy and Depression MST (magnetic seizure therapy) tdcs (transcranial direct-current stimulation) TENS (transcutaneous electrical nerve stimulation) CES (cranial electrical stimulation) EPI-fMRI (echo planar functional magnetic resonance imaging) Transcranial pulsed ultrasound Impact of Persistent Depression The impact on health resource use is profound Excess health care visits are for medical evaluation of untreated depression symptoms (eg, chest pain, backache, chronic pain) Excess utilization of health care resources overall Increases are evident on both direct and indirect costs 30% of depressed patients attempt suicide Nearly half of these complete (> 19,000 suicides/year in the United States) Katon WJ. Biol Psychiatry. 2003;54(3): Rugulies R. Am J Prev Med. 2002;23(1): Fawzy FI, et al. Arch Gen Psychiatry. 1993;50(9): Fawzy FI, et al. Arch Gen Psychiatry. 2003;60(1): Cook JM, et al. Am J Geriatr Psychiatry. 2002;10(4): Eaton WW, et al. Diabetes Care. 1996;19(10): American Foundation for Suicide Prevention. Major Depression is a Leading Health Risk in the Workplace Setting Top 10 health conditions by annual medical, drug, absenteeism, and presenteeism costs per 1000 FTEs Even without disability costs being included the combined medical, pharmacy, absenteeism and presenteeism costs of depression, and fatigue are far more costly than previously realized the cost ranking of health conditions [including productivity loss] is significantly different from the more traditional cost ranking of medical or pharmacy costs alone. an integrated approach of combining medical or pharmacy costs [with lost productivity] provides a more complete and actionable financial assessment for FTE = full time equivalent. employers. Loeppke R, et al. J Occup Environ Med. 2009;51(4): Cost Impact of Depression on Associated Illnesses STAR*D Study Demonstrates That Current Treatments Have Limited Effectiveness Collins RL, et al. Manag Care. 2006;15(10 Suppl 9):3-9. STAR*D = Sequenced Treatment Alternatives to Relieve Depression; HAM-D = Hamilton Rating Scale for Depression. Trivedi MH, et al. Am J Psychiatry. 2006;163(1): Rush AJ, et al. Am J Psychiatry. 2006;163(11): Fava M, et al. Am J Psychiatry. 2006;163(7): McGrath PJ, et al. Am J Psychiatry. 2006;163(9):
2 Likelihood of Discontinuing Treatment Increases with Each New Medication Attempt Systemic Drug Side Effects Weight Gain Fatigue Constipation Headache/ Migraine Diarrhea Abnormal Nausea Ejaculation Drowsiness Impotence Relapse during Long-Term Follow-Up STAR*D Study Results The higher the level of treatment resistance prior to remission, the faster the relapse in long-term follow-up Insomnia Sweating Decreased Libido Tremor Nervous Anxiety Treatment Discontinuation Increased Appetite Side Effects Decreased Weakness Appetite Dry Mouth Dizziness Trivedi MH, et al. Am J Psychiatry. 2006;163(1): Rush AJ, et al. Am J Psychiatry. 2006;163(11): Fava M, et al. Am J Psychiatry. 2006;163(7): McGrath PJ, et al. Am J Psychiatry. 2006;163(9): Rush AJ, et al. Am J Psychiatry. 2006;163(11): TMS How Do ECT and TMS Differ? Application of electromagnetic induction described by Michael Faraday in 1839 Faraday s Law: a timevarying magnetic field induces an electric current that runs perpendicular to the time-varying motion of the magnetic field Clinical application: pulsed magnetic fields can induce electrical currents in brain tissues and neurons Faraday M. Experimental Research in Electricity. Volume 1. London: Quaritch; 1839:1-15. Barker AT. J Clin Neurophysiol. 1991;8(1): Barker AT, et al. Lancet. 1985;11(8437): Herwig U, et al. Biol Psychiatry. 2001;50(1): Hz rtms 1 Hz TMS Speer AM, et al. Biol Psychiatry. 2000;48(12): Speer AM, et al. Biol Psychiatry. 2000;48(12):
3 ECT and rtms vastly differ Key Take-Aways High Frequency rtms (> 1 Hz) enhances cortical excitability Mechanism of Action for TMS Faraday s Law The Forgotten Half of the Truth C Electricity is the Currency of the Brain All of synaptic pharmacology simply serves to transmit electrical signals to the next neuron Michael Faraday ( ) Cortex TMS Coil The induced electromotive force in any closed circuit is equal to the time rate of change of the magnetic flux through the circuit The Brain is an Electrochemical Organ George MS, et al (Eds). Transcranial Magnetic Stimulation in Clinical Psychiatry. Arlington, VA: American Psychiatric Publishing, Inc.; TMS Mechanism of Effect TMS Increases Neurogenesis in Hippocampal Dentate Gyrus Acute effects of pulsed magnetic fields in the brain: Induction of localized electric current Depolarization of neurons in superficial cerebral cortex Alteration in cerebral blood flow and metabolic activity; neurotransmitter release Distant action on connected circuits Sack AT, et al. Brain Res Brain Res Rev. 2003;43(1): Ueyama E, et al. Psychiatry Clin Neurosci. 2011;65(1):77-81.
4 Treating the Brain as an Electrochemical Target Brain activity can be altered: Chemically (eg, via drugs) or Electrically (eg, via TMS) Drug action is anatomically diffuse and systemic TMS is focused, noninvasive and non-systemic Prefrontal Cortex Ventromedial Prefrontal Cortex Amygdala Major brain regions known to be involved in mood regulation Biological Effects of TMS Acute Effects Induces electric current Depolarizes neurons in superficial cortex Leads to local and trans-synaptic changes in brain activity Example Left prefrontal TMS 22 depressed individuals Activation demonstrated at site of stimulation and also at synaptically connected cortical and subcortical regions Pizzagalli DA. Neuropsychopharmacology. 2011;36(1): Li X, et al. Biol Psychiatry. 2004;55(9): Teneback CC, et al. J Neuropsychiatry Clin Neurosci. 1999;11(4): Biological Changes with rtms in Human Studies rtms produces changes in PFC and paralimbic blood flow with DLPFC stimulation Increased output of TSH in association with acute mood change in depression Normalization of the DST with rtms DST = dexamethasone suppression test; DLPFC = dorsolateral prefrontal cortex; PFC = prefrontal cortex; TSH = thyroid-stimulating hormone. Biological Effects of TMS (cont d) Chronic Effects Specific outcome is dependent upon stimulation parameters Alteration of monoamine concentrations β-receptor, serotonin-receptor modulation Induction of neurogenesis genes (eg, BDNF) Plasticity, LTD/LTP effects Local GABA, glutamate effects Stimulation of the DLPFC alters functional activity of the anterior cingulate and deeper limbic regions BDNF = brain-derived neurotrophic factor; LTD = long-term depression; LTP = long-term potentiation; GABA = gamma-aminobutyric acid. Lisanby SH, et al. Depress Anxiety. 2000;12(3): Kim EJ, et al. Neurosci Lett. 2006;405(1-2): Shajahan PM, et al. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(5): Teneback CC, et al. J Neuropsychiatry Clin Neurosci. 1999;11(4): Epstein CM, et al. Neurology. 1990;40(4): George MS, et al. Neuroreport. 1995;6(14): Post A, et al. J Psychiatr Res. 2001;35(4): Pooled effects of 1 Hz prefrontal TMS in 5 healthy adults, 120% MT, BOLD fmri, P <.001, cluster P <.05 for display Prefrontal TMS Effects Limbic Blood Flow Different Left DLPFC TMS Targets Show Variability in Resting State Functional Connectivity Nahas Z, et al. Biol Psychiatry. 2001;50(9): Fox MD, et al. Biol Psychiatry. 2012;72(7):
5 Differences in Resting State Functional Connectivity between More Effective vs Less Effective DLPFC Stimulation Sites Prefrontal TMS Induces Dopamine Release in Ipsilateral Caudate pulse 1s Hz, total 450 Fox MD, et al. Biol Psychiatry. 2012;72(7): Strafella AP, et al. J Neurosci. 2001;21(15):RC157. Declining Amygdala and Prefrontal Activity with Worsening Depression Cortical Governance over Limbic Activity Could we wake this up with TMS? Post A, et al. J Psychiatr Res. 2001;35(4): Alexander GE, et al. Annu Rev Neurosci. 1986;9: Clinical Safety and Tolerability Considerations What s common, what s not No evidence of cognitive sequelae Common adverse events Self-limited headache after treatment (~ 1 in 4) Cutaneous discomfort during stimulation (~ 1 in 6) Pain during stimulation (~ 3% 5%) Risk of seizure 9 cases reported in the world literature with rtms Self-limited No reported sequelae or progression to seizure disorder No additional cases since inception of 1998 guidelines Key Take-Aways Synaptic pharmacology serves to transmit electrical signals to the next neuron; In clinical practice, rtms uses pulsed magnetic fields to induce electrical current in brain tissue and neurons One goal of rtms is to reset cortical and thalamocortical oscillators, leading to increased flexibility in network formations rtms modulates monoamines, glutamate, GABA, as well as intracellular plasticity cascades Post A, et al. J Psychiatr Res. 2001;35(4):
6 Initial TMS Antidepressant Studies Clinical Trial Data Past and Present 1,2 = randomized, controlled, remainder of studies were open. George MS, et al (Eds). Transcranial Magnetic Stimulation in Clinical Psychiatry. Arlington, VA: American Psychiatric Publishing, Inc.; Comparative Analysis of Effect Size: TMS Therapy vs Medications TMS Therapy Week 4 (HAM-D-17) Critique of Early Studies Sample sizes generally small Study design: single blinded Some subsets of robust responders but generally reduction in baseline scores < 50% Questions as to adequacy of sham in terms of blind and block of magnetic stimulus Does TMS have antidepressant effects that are not meaningful clinically? 0.0 Overall Population 1 AD Failure Subgroup O Reardon JP, et al. Biol Psychiatry. 2007;62(11): Janicak PG, et al. J Clin Psychiatry. 2008;69(2): Khan A, et al. Arch Gen Psychiatry. 2000;57(4): Kozel FA, et al. J Psychiatr Pract. 2002;8(5): Meta-Analysis of Left DLPFC rtms Included 12 controlled trials (n = 230) Mean effect size 0.53 (CI ) Comparable effect to antidepressants Would need at a minimum 20 negative studies to override this result TMS Therapy Demonstrates a Clear Separation between Active and Sham Treatment RCT Key Outcome Measure MADRS Change Score > 3 Reduction in Depressive Symptoms at Week 4 P =.0018 P =.0006 P =.0063 Kozel FA, et al. J Psychiatr Pract. 2002;8(5): LOCF analysis of intent-to-treat population. Demitrack MA, et al. Psychopharmacol Bull. 2009;42(2):5-38.
7 Independent Study Reinforces Efficacy for TMS Consistent Response and Remission Rates across a Broad Range of Treatment Resistance 1 in 2 Patients Respond, 1 in 3 Patients Achieve Remission Naturalistic, Open Label Treatment Utilization and Outcomes Study Mark S. George, MD; Sarah H. Lisanby, MD; David Avery, MD; William M. McDonald, MD; Valerie Durkalski, PhD; Martina Pavlicova, Phd; Berry Anderson, Phd, RN; Ziad Nahas, MD; Peter Bulow, MD; Paul Zarkowski, MD; Paul E. Holtzheimer III, MD; Theresa Schwartz, MS; Harold A. Sackeim, PHD NIMH-sponsored Optimization of TMS (OPT-TMS) Study Independent of industry Rigorous RCT; active sham-controlled (1:1 randomization), duration-adaptive design with 3 weeks of daily weekday treatment (fixed-dose phase) followed by continued blinded treatment for up to another 3 weeks in improvers 190 patients treated at 4 premier academic sites Primary outcome measure: Percent Remission at 3 weeks 4 greater likelihood of achieving remission with active treatment vs sham treatment George MS, et al. Arch Gen Psychiatry. 2010;67(5): Patient reported outcomes (PHQ-9) were consistent with physician-rated outcomes LOCF analysis of intent-to-treat population. CGI-S outcomes in acute phase. *0 1 adequate antidepressant medications; ** 2 adequate antidepressant medications. PHQ-9 = 9-item Patient Health Questionnaire. Carpenter LL, et al. Depress Anxiety. 2012;29(7): TMS Represents a Cost Saving over Treatment-As-Usual TMS Therapy in the Care Continuum TMS represents a cost savings per patient per year compared to current standard of care: US $1123 Without productivity and work loss costs included in the model (Payer Perspective) US $7621 With productivity and work loss costs included in the model (Employer Perspective) Simpson KN, et al. Adv Ther. 2009;26(3): SSRI = selective serotonin reuptake inhibitor; SNRI = serotonin-norepinephrine reuptake inhibitor; NDRI = norepinephrine-dopamine reuptake inhibitor; MAOI = monoamine oxidase inhibitor; TCA = tricyclic antidepressant. Antidepressant Effect of dtms in Relation to the Number of Failed Pharmacotherapy Trials TMS Therapy Modulates Discrete Deep Brain Regions Treatment with TMS reduces hyperconnectivity within the default mode network (ventromedial prefrontal cortex, pregenual anterior cingulate cortex, thalamus, and precuneus) Levkovitz Y, et al. World Psychiatry. 2015;14(1): Liston C, et al. Biol Psychiatry. 2014;76(7):
8 TMS Modulates EEG Gamma Frequency in Distributed Brain Regions Treatment with TMS Therapy is associated with an enhancement of gamma band activity in DLPFC and anticorrelated reduction of activity in the precuneus Precuneus Long-Term Treatment Outcomes of TMS in Naturalistic Setting 257 patients with medication-resistant unipolar depression received TMS and followed post-treatment for 52 weeks At the end of acute treatment 120 patients met criteria for either response or remission. Of those, 75 (62.5%) met response criteria throughout the follow-up period Of the entire cohort, 93 patients (36.2%) received reintroduction of TMS at some point during the 52-week follow up. Average number of TMS days was 16.2 days EEG = electroencephalogram. Kito S, et al. Brain Stimul. 2014;7(1): Dunner DL, et al. J Clin Psychiatry. 2014;75(12): Need for Maintenance rtms In principle, the best way to maintain benefit would be rtms sessions Options include transition back to ADM or rtms sessions at reduced frequency Maintenance ECT may be a model in this regard Very small amount of data with maintenance rtms TMS Maintenance as a Substitute for Maintenance ECT A Case Study TMS is an efficacious, well-tolerated, non-invasive brain stimulation treatment for MDD ECT is an effective maintenance treatment for depression, but is not tolerated by some patients and declined by others ADM = antidepressant medication. Li X, et al. Depress Anxiety. 2004;20(2): Benadhira R, et al. Am J Psychiatry. 2005;162(1):193. Abraham G, et al. Can J Psychiatry. 2002;47(4):386. Cristancho MA, et al. J ECT. 2013;29(2): Change in BDI Scores from Initial Observation (baseline prior to first TMS session) to 3 months, 6 months, and Last Observation No Efficacy/Effectiveness Gap 307 real-world US patients, on medication, 58% response, 37% remission, average 28 sessions 100 patients, U Penn practice model, 50% response, 25% remission BDI = Beck Depression Inventory. Cristancho MA, et al. J ECT. 2013;29(2): Carpenter LL, et al. Depress Anxiety. 2012;29(7): Connolly KR, et al. J Clin Psychiatry. 2012;73(4):e567-e573.
9 TMS Improves Evoked-fMRI Cortical Responses after TBI Future Applications TBI = traumatic brain injury. Lu H, et al. Sci Rep. 2015;5: TMS Restores Cortical Excitability after TBI A Summary of Our Current Understanding of Factors That Contribute to Post-Stroke Impairment LFP = local field potential; MUA = multi-unit activity. Lu H, et al. Sci Rep. 2015;5: Auriat AM, et al. Front Neurol. 2015;6:226. Performance on Measures of Discourse Productivity before and 2 Months after Receiving Real rtms Finding the Right Words: TMS Improves Discourse Productivity in Non-Fluent Aphasia after Stroke N = 10. Medina J, et al. Aphasiology. 2012;26(9): Medina J, et al. Aphasiology. 2012;26(9):
10 TMS-Induced Global Propagation of Transient Phase Resetting Associated with Directional Information Flow stms Has Been Shown to be Effective for the Acute Treatment of Migraine Kawasaki M, et al. Front Hum Neurosci. 2014;8:173. CSD = cortical spreading depression; TMS = single pulse transcranial magnetic stimulation. Andreou AP, et al. Brain. 2016;139(Pt 7): The Impact of TMS on Mechanically and Chemically Induced CSD rtms Could be a Safe and Effective Treatment Option for Patients with Chronic Low Back Pain Resulting in Depression and Insomnia Andreou AP, et al. Brain. 2016;139(Pt 7): ISI = Insomnia Severity Index; NRS = Pain Numerical Rating Scale; PDI = Pain Disability Index. Park EJ, et al. Korean J Pain. 2014;27(3): TMS for the Treatment of Pharmacoresistant Nondelusional Auditory Verbal Hallucinations in Dementia AVHs are known as a core symptom of schizophrenia, but also occur in a number of other conditions, not least in neurodegenerative disorders such as dementia In the last decades, TMS emerged as a valuable therapeutic approach towards several neurological and psychiatric diseases, including AVHs The study authors reported a case of a 76-year-old woman with vascular-degenerative brain disease, complaining of threatening AVHs The patient was treated with a high-frequency temporoparietal (T3P3) rtms protocol for 15 days A considerable reduction of AVHs in frequency and content (no more threatening) was observed. Although further research is needed, this seems an encouraging result AVH = auditory verbal hallucination. Marras A, et al. Case Rep Psychiatry. 2013;2013: Assessing and Stabilizing Aberrant Neuroplasticity in Autism Spectrum Disorder: The Potential Role of TMS TMS has rapidly evolved to become a widely used, safe, and non-invasive neuroscientific tool to investigate a variety of neurophysiological processes, including neuroplasticity The diagnostic and therapeutic potential of TMS in ASD is beginning to be realized ASD = autism spectrum disorder. Desarkar P, et al. Front Psychiatry. 2015;6:124.
11 Irritability, Lethargy, and Hyperactivity Rating Scores Decreased Significantly Post-TMS Stereotype Behavior, Ritualistic Behavior, and Total RBS Scores Decreased Significantly Casanova MF, et al. Front Hum Neurosci. 2014;8:851. RBS = Repetitive Behavior Scale. Casanova MF, et al. Front Hum Neurosci. 2014;8:851. Forest Plot of Comparison of Auditory Hallucination Scales in Active rtms vs Sham Stimulation Forest Plot of Comparison of Response Rate in Active rtms vs Sham Stimulation (Auditory Hallucination of Patients with Schizophrenia Spectrum Disorders) Zhang Y, et al. Neural Regen Res. 2013;8(28): Zhang Y, et al. Neural Regen Res. 2013;8(28): The ERP Waveforms and Brain Topographic Maps of Tinnitus Patients before rtms The ERP Waveforms and Brain Topographic Maps of Tinnitus Patients after rtms ERP = event-related potential. Yang H, et al. PLoS One. 2013;8(8):e Yang H, et al. PLoS One. 2013;8(8):e70831.
12 TMS and Postoperative Pain One rtms Session Cuts Cumulative Morphine Use by 40% TMS half-life? RCT, 20 Gastric Bypass Patients, L DLPFC, 20 minutes, 10 Hz, 100% rmt The use of TMS for postoperative pain off-label. rmt = resting motor threshold. Borckardt JJ, et al. Anesthesiology. 2006;105(3): Borckardt JJ, et al. Anesthesiology. 2006;105(3): TMS Anti-Suicide Study High dose, 3-day adjunctive TMS study on inpatients admitted for suicidal ideation Randomized, sham-controlled N = 45, 2 sites Ralph H. Johnson VA Medical Center, Walter Reed National Military Medical Center 2 years 18,000 stimuli/day, 54,000 total Active TMS Significantly Reduced Suicidal Ideation Beck Suicide Scale Visual Analog Scale I am currently bothered by thoughts of suicide George MS, et al. Brain Stimul. 2014;7(3): SSI = Scale of Suicidal Ideation. George MS, et al. Brain Stimul. 2014;7(3): Future Applications Key Take-Aways Psychiatry Schizophrenia Bipolar depression PTSD OCD Preliminary human data suggest the potential application of TMS in these conditions Neurology Stroke rehab Chronic pain Trigeminal neuralgia Headache ADHD Tinnitus Epilepsy Parkinson s disease Early rtms trials were flawed in that they were inconsistent in the frequency and number of treatments given More recent studies have shown that rtms is equal to, if not superior to pharmacotherapy for TRD A very recent study has demonstrated that high dose, 3-day adjunctive rtms reduces suicidal ideation PTSD = posttraumatic stress disorder; OCD = obsessive-compulsive disorder; ADHD = attentiondeficit/hyperactivity disorder. Serafini G, et al. Neuropsychobiology. 2015;71(3):
13 Further Reading Recommended Clinical Practice Essentials Training Roles and responsibilities Establishing a treatment plan Informed consent Safety considerations Outcome evaluation Post-treatment planning George MS, Belmaker RH. Transcranial Magnetic Stimulation in Clinical Psychiatry. Arlington, VA: American Psychiatric Publishing, Inc.; Higgins ES, George MS. The Neuroscience of Clinical Psychiatry: The Pathophysiology of Behavior and Mental Illness. Philadelphia, PA: Lippincott; Higgins ES, George MS. Brain Stimulation Therapies for Clinicians. Washington, DC: American Psychiatric Publishing; Perera T, et al. The Clinical TMS Society Consensus Review and Treatment Recommendations for TMS Therapy for Major Depressive Disorder. Brain Stimul. 2016;9(3): Clinical Recommendations Indicated Patient Population: The labeled indication for use for the TMS therapy states that, TMS therapy is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode. Recommendation 1: TMS therapy is recommended as an acute treatment for symptomatic relief of depression in the indicated patient population. [Strength of the recommendation: A, consistent evidence from Level 1 studies] Recommendation 2: TMS therapy is recommended for use as a subsequent option in patients who previously benefited from an acute treatment course and are experiencing a recurrence of their illness (continuation or maintenance). [Strength of the recommendation: A, consistent evidence from Level 1 studies] Perera T, et al. The Clinical TMS Society Consensus Review and Treatment Recommendations for TMS Therapy for Major Depressive Disorder. Brain Stimul. 2016;9(3): Clinical Recommendations (cont d) Recommendation 3: TMS therapy can be administered with or without the concomitant administration of antidepressant or other psychotropic medications. [Strength of the recommendation: B, Extrapolation from Level 2 Studies] Recommendation 4: TMS therapy can be used as a continuation or maintenance treatment for patients who benefit from an acute course. [Strength of the recommendation: A, consistent evidence from Level 1 studies] Recommendation 5: TMS therapy can be reintroduced in patients who are relapsing into depression after initially responding to TMS treatment. [Strength of the recommendation: B, Extrapolation from Level 2 studies] Perera T, et al. The Clinical TMS Society Consensus Review and Treatment Recommendations for TMS Therapy for Major Depressive Disorder. Brain Stimul. 2016;9(3): CPT I Codes for Therapeutic TMS Should I start my own TMS practice? Code Description Therapeutic Repetitive Transcranial Magnetic stimulation (TMS) treatment; initial, including cortical mapping, motor threshold determination, delivery and management (Report only once per course of treatment) (Do not report in conjunction with 95928, 95929, 90868, 90869) Subsequent delivery and management, per session Subsequent motor threshold redetermination with delivery and management A good estimate of startup cost for equipment and space requirements ranges between $100,000 to $150,000 Additional monies for staff cost must be considered as well (TMS coordinator, TMS treater, billing specialist) Insurance coverage varies state to state, as do reimbursement rates Medicare is the only carrier that covers nationally Perera T, et al. The Clinical TMS Society Consensus Review and Treatment Recommendations for TMS Therapy for Major Depressive Disorder. Brain Stimul. 2016;9(3):
Transcranial Magnetic Stimulation: Scientific Underpinnings and Practical Applications
Transcranial Magnetic Stimulation: Scientific Underpinnings and Practical Applications Jon Draud, MS, MD Clinical Professor of Psychiatry University of Tennessee College of Medicine Memphis, Tennessee
More informationTodd Hutton, M.D. Karl Lanocha, M.D Richard Bermudes, M.D. Kimberly Cress, M.D.
Transcranial Magnetic Stimulation: What You Need To Know Todd Hutton, M.D. Karl Lanocha, M.D Richard Bermudes, M.D. Kimberly Cress, M.D. Disclosures Todd Hutton, M.D. Speaker for Neuronetics Board of Directors,
More informationTranscranial Magnetic Stimulation for the Treatment of Depression
Transcranial Magnetic Stimulation for the Treatment of Depression Paul E. Holtzheimer, MD Associate Professor Departments of Psychiatry and Surgery Geisel School of Medicine at Dartmouth Dartmouth-Hitchcock
More informationTranscranial Magnetic Stimulation (TMS)
Transcranial Magnetic Stimulation (TMS) The treatment coil produces MRI-strength magnetic field pulses. Magnetic field pulses pass unimpeded through the cranium for 2-3 cm. and induce a small electric
More informationTranscranial Magnetic Stimulation
Transcranial Magnetic Stimulation Date of Origin: 7/24/2018 Last Review Date: 7/24/2018 Effective Date: 08/01/18 Dates Reviewed: 7/24/2018 Developed By: Medical Necessity Criteria Committee I. Description
More informationBRAIN STIMULATION AN ALTERNATIVE TO DRUG THERAPY IN MATERNAL DEPRESSION?
BRAIN STIMULATION AN ALTERNATIVE TO DRUG THERAPY IN MATERNAL DEPRESSION? Kira Stein, MD Medical Director West Coast Life Center Sherman Oaks, California CA Maternal Mental Health Initiative - 2013 2013
More informationTreatment of Depression: A Brief History
2500 82nd Place Urbandale, Ia Treatment of Depression: A Brief History 1960 s to Present Community Based Services SSRI Antidepressants SNRI Antidepressants 1970 s to present 20% of patients do not respond
More informationNeuromodulation Approaches to Treatment Resistant Depression
1 Alternative Treatments: Neuromodulation Approaches to Treatment Resistant Depression Audrey R. Tyrka, MD, PhD Assistant Professor Brown University Department of Psychiatry Associate Chief, Mood Disorders
More informationFrequently Asked Questions FAQS. NeuroStar TMS Therapies
Frequently Asked Questions FAQS NeuroStar TMS Therapies Provided by Dr Terrence A. Boyadjis MD 790 E Market Street Suite 245 West Chester, PA 19382 610.738.9576 FAQS About TMS Therapies Page 1 NeuroStar
More informationTherapeutic Neuromodulation: Overview of a Novel Treatment Platform
Therapeutic Neuromodulation: Overview of a Novel Treatment Platform David G. Brock, MD; and Mark A. Demitrack, MD Shutterstock David G. Brock, MD, is Medical Director, Neuronetics, Inc. Mark A. Demitrack,
More informationFDA CLEARS NEUROSTAR TMS THERAPY FOR THE TREATMENT OF DEPRESSION
FOR IMMEDIATE RELEASE FDA CLEARS NEUROSTAR TMS THERAPY FOR THE TREATMENT OF DEPRESSION First and Only Non-systemic and Non-invasive Treatment Cleared for Patients Who Have Not Benefited From Prior Antidepressant
More informationRemission From Depression Is Possible
Remission From Depression Is Possible About Depression Over 350 million people worldwide suffer from depression 1 While medications may help manage symptoms of depression, many patients are not satisfied
More informationStatement on Repetitive Transcranial Magnetic Stimulation for Depression. Position statement CERT03/17
Statement on Repetitive Transcranial Magnetic Stimulation for Depression Position statement CERT03/17 Approved by the Royal College of Psychiatrists, Committee on ECT and Related Treatments: February 2017
More informationPatient Manual Brainsway Deep Transcranial Magnetic Stimulation (Deep TMS) System for Treatment of Major Depressive Disorder
Dr. Zahida Tayyib www.mvptms.com Patient Manual Brainsway Deep Transcranial Magnetic Stimulation (Deep TMS) System for Treatment of Major Depressive Disorder If you are considering Brainsway Deep treatment
More informationWhat is Repetitive Transcranial Magnetic Stimulation?
rtms for Refractory Depression: Findings and Future Jonathan Downar, MD PhD Asst Professor, Dept of Psychiatry University of Toronto, Canada Co-Director, rtms Clinic Toronto Western Hospital University
More informationThe Next Chapter in Brain Stimulation Therapy
The Next Chapter in Brain Stimulation Therapy Outline I. Depression and Treatment Resistant Depression Barriers to Treatment Treatment Options Cost and Impact of Depression II. Electroconvulsive Therapy
More informationSome newer, investigational approaches to treating refractory major depression are being used.
CREATED EXCLUSIVELY FOR FINANCIAL PROFESSIONALS Rx FOR SUCCESS Depression and Anxiety Disorders Mood and anxiety disorders are common, and the mortality risk is due primarily to suicide, cardiovascular
More informationCase 2:15-cv MWF-JPR Document Filed 03/20/17 Page 1 of 36 Page ID #:388 EXHIBIT 1
Case 2:15-cv-07074-MWF-JPR Document 65-10 Filed 03/20/17 Page 1 of 36 Page ID #:388 EXHIBIT 1 Case 2:15-cv-07074-MWF-JPR Document 65-10 Filed 03/20/17 Page 2 of 36 Page ID #:389 Cigna Medical Coverage
More informationBrain Stimulation. Berry S. Anderson, PhD, RN Mary Rosedale, PhD, PMHNP-BC, NEA-BC Theresa Kormos, PMHCNS-BC Cindy Brown, BSN, RN
Brain Stimulation American Psychiatric Nurses Association 24th Annual Conference October 16, 2010 Kentucky International Convention Center Louisville, Kentucky 1 Berry S. Anderson, PhD, RN Mary Rosedale,
More informationTranscranial Magnetic Stimulation and Cranial Electrical Stimulation (CES) as a Treatment of Depression and Other Psychiatric/Neurologic Disorders
Transcranial Magnetic Stimulation and Cranial Electrical Stimulation (CES) as a Treatment of Depression and Other Psychiatric/Neurologic Disorders Policy Number: 2.01.50 Last Review: 10/2017 Origination:
More informationRepetitive Transcranial Magnetic Stimulation as a for Treatment of Refractory Depression and other Psychiatric/Neurologic Disorders
Repetitive Transcranial Magnetic Stimulation as a for Treatment of Refractory Depression and other Psychiatric/Neurologic Disorders Policy Number: Original Effective Date: MM.12.015 08/01/2014 Line(s)
More informationrtms Versus ECT The Future of Neuromodulation & Brain Stimulation Therapies
rtms Versus ECT The Future of Neuromodulation & Brain Stimulation Therapies rtms Treatment Equipment rtms Equipment Positioning of coil ECT & rtms Innovative Treatment Options for Patients Only a fraction
More informationThe New Clinical Science of ECT
The New Clinical Science of ECT C. Edward Coffey, MD Professor of Psychiatry & Behavioral Sciences, and of Neurology Baylor College of Medicine Houston, Texas Fellow and Past President, International Society
More informationOriginal Effective Date: 8/28/2013. Subject: Transcranial Magnetic Stimulation for the Treatment of Major Depression
Subject: Transcranial Magnetic Stimulation for the Treatment of Major Depression Guidance Number: MCG-104 Revision Date(s): Original Effective Date: 8/28/2013 Medical Coverage Guidance Approval Date: 8/28/2013
More informationRepetitive Transcranial Magnetic Stimulation (rtms)
Page 1 of 33 Medical Policies - Mental Health Repetitive Transcranial Magnetic Stimulation (rtms) Print Number: PSY301.015 Effective Date: 07-01-2014 Coverage: Initial rtms Treatment Repetitive transcranial
More informationTherapeutic Uses of Noninvasive Brain Stimulation Current & Developing
Therapeutic Uses of Noninvasive Brain Stimulation Current & Developing Alvaro Pascual-Leone, MD, PhD Berenson-Allen Center for Noninvasive Brain Stimulation Harvard Catalyst Beth Israel Deaconess Medical
More informationInterventions for Relapsing Depression: TMS, ECT, and Ketamine
Interventions for Relapsing Depression: TMS, ECT, and Ketamine MDD top cause of disability; suicide only top-10 cause of death currently increasing. 10-15% lifetime prevalence A third of patients do not
More informationRepetitive transcranial magnetic stimulation for depression
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Interventional procedure consultation document Repetitive transcranial magnetic stimulation for depression Depression causes low mood or sadness that can
More informationNonpharmacologic Interventions for Treatment-Resistant Depression. Public Meeting December 9, 2011
Nonpharmacologic Interventions for Treatment-Resistant Depression Public Meeting December 9, 2011 New England CEPAC Goal: To improve the application of evidence to guide practice and policy in New England
More informationInterventions for Relapsing Depression: TMS, ECT, and Ketamine
Interventions for Relapsing Depression: TMS, ECT, and Ketamine MDD top cause of disability; suicide only top-10 cause of death currently increasing. 10-15% lifetime prevalence A third of patients do not
More informationAmerican University of Beirut University of Minnesota present. Depression: A complex landscape
Medial and Lateral Prefrontal Cortex Neuromodulation Therapies in Depression: A Continuum Ziad Nahas, MD, MSCR Professor and Vice Chair for Clinical Affairs Department of Psychiatry; University of Minnesota
More informationLEASE DO NOT COPY. Setting up atms Clinic
Setting up atms Clinic Daniel Press, M.D. Assistant Professor in Neurology, Harvard Medical School and Beth Israel Deaconess Medical Center Contents Safety and training of personnel Equipment Certification
More informationSetting up atms Clinic. Daniel Press, M.D. Assistant Professor in Neurology, Harvard Medical School and Beth Israel Deaconess Medical Center
Setting up atms Clinic Daniel Press, M.D. Assistant Professor in Neurology, Harvard Medical School and Beth Israel Deaconess Medical Center Contents Safety and training of personnel Equipment Certification
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abuse alcohol, aggression and, 52 53 substance, aggression and, 52 54 ACE. See Aid to Capacity Evaluation (ACE). AEDs. See Antiepileptic
More informationTranscranial magnetic stimulation has become an increasingly
Within-Session Mood Changes From TMS in Depressed Patients Tobias Dang, M.D. David H. Avery, M.D. Joan Russo, Ph.D. Transcranial magnetic stimulation has become an increasingly well studied tool in neuropsychiatry.
More informationTranscranial Magnetic Stimulation
Transcranial Magnetic Stimulation Scientific evidence in major depression and schizophrenia C.W. Slotema Parnassia Bavo Group The Hague, the Netherlands Faraday s law (1831) Electrical current magnetic
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Transcranial Magnetic Stimulation (TMS) Page 1 of 21 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Transcranial Magnetic Stimulation (TMS) Vagus Nerve
More informationFocally Electrically Administered Seizure Therapy (FEAST) and other developments in stimulatory techniques.
Focally Electrically Administered Seizure Therapy (FEAST) and other developments in stimulatory techniques. Mark S. George, MD Distinguished Professor of Psychiatry, Radiology and Neurology Layton McCurdy
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Transcranial Magnetic Stimulation (TMS) Page 1 of 24 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Transcranial Magnetic Stimulation (TMS) Vagus Nerve
More informationNOW I M A NEUROSTAR. Let Your Best Self Shine
NOW I M A NEUROSTAR. Let Your Best Self Shine It s Time for a New You NeuroStar Advanced Therapy is an in-office treatment that requires no anesthesia or sedation. You are awake and alert during treatment
More informationSetting up a TMS Treatment Program
Setting up a TMS Treatment Program Alvaro Pascual-Leone, M.D., Ph.D. Professor in Neurology Harvard Medical School Beth Israel Deaconess Medical Center Daniel Cohen, M.D., M.M.Sc. Instructor in Neurology
More informationTRANSCRANIAL MAGNETIC STIMULATION
TRANSCRANIAL MAGNETIC STIMULATION Optum Behavioral Clinical Policy Policy Number: BH727BCPTMS_112017 Effective Date: November, 2017 Table of Contents Page BENEFIT CONSIDERATIONS... 1 COVERAGE RATIONALE...
More informationDisclosures. Objectives. The Neurobiology of Therapeutic Neuromodulation: Implications for Psychiatric Mental Health Nurses
The Neurobiology of Therapeutic Neuromodulation: Implications for Psychiatric Mental Health Nurses American Psychiatric Nurses Association 26 th Annual Conference November 7, 2012 Pittsburgh, Pennsylvania
More information( Transcranial Magnetic Stimulation, TMS) TMS, TMS TMS TMS TMS TMS TMS Q189
102 2004 35 2 3 : 1 2 2 ( 1 DK29220 ; 2 100083) ( Transcranial Magnetic Stimulation TMS) TMS TMS TMS TMS TMS TMS TMS ; ; ; Q189 Transcranial Magnetic Stimulation ( TMS) : Physiology Psychology Brain Mapping
More informationClinical Perspective on Conducting TRD Studies. Hans Eriksson, M.D., Ph.D., M.B.A. Chief Medical Specialist, H. Lundbeck A/S Valby, Denmark
Clinical Perspective on Conducting TRD Studies Hans Eriksson, M.D., Ph.D., M.B.A. Chief Medical Specialist, H. Lundbeck A/S Valby, Denmark Overview of Presentation Treatment-Resistant Depression (TRD)
More informationBME 701 Examples of Biomedical Instrumentation. Hubert de Bruin Ph D, P Eng
BME 701 Examples of Biomedical Instrumentation Hubert de Bruin Ph D, P Eng 1 Instrumentation in Cardiology The major cellular components of the heart are: working muscle of the atria & ventricles specialized
More informationEfficacy and Safety of Transcranial Magnetic Stimulation in Patients with Depression
Showa Univ J Med Sci 30 1, 97 106, March 2018 Original Efficacy and Safety of Transcranial Magnetic Stimulation in Patients with Depression Yu KAWAGUCHI 1 and Akira IWANAMI 2 Abstract : Transcranial magnetic
More information(U) USSOCOM. (U) Magnetic qeeg guided Resonance Therapy (MeRT)
United States Special Operations Command (U) USSOCOM MeRT Clinical Trial for Treatment of TBI COL Mark Baggett, Ph.D., US Army USSOCOM Command Psychologist Date: 14 Feb 2018 1 (U) Magnetic qeeg guided
More informationBringing. to patients with depression
Bringing to patients with depression Hope is knowing remission from depression is possible Depression is a serious illness that affects approximately 350 million people worldwide. 1 While medications may
More informationLaurence M. Hirshberg, Sufen Chiu, and Jean A. Frazier
EMERGING INTERVENTIONS Foreword Melvin Lewis xi Preface Laurence M. Hirshberg, Sufen Chiu, and Jean A. Frazier xiii Emerging Brain-Based Interventions for Children and Adolescents: Overview and Clinical
More informationTranscranial Magnetic Stimulation and Cranial Electrical Stimulation (CES) as a Treatment of Depression and Other Psychiatric/Neurologic Disorders
Transcranial Magnetic Stimulation and Cranial Electrical Stimulation (CES) as a Treatment of Depression and Other Psychiatric/Neurologic Disorders Policy Number: 2.01.50 Last Review: 10/2014 Origination:
More information2018 Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD Lundbeck, LLC.
Neuromodulation Techniques: State of the Science Philip G. Janicak, MD Adjunct Professor Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine Consultant
More informationTranscranial Magnetic Stimulation as a Treatment of Depression and Other Psychiatric/Neurologic Disorders Corporate Medical Policy
Transcranial Magnetic Stimulation as a Treatment of Depression and Other Psychiatric/Neurologic Disorders Corporate Medical Policy File name: Transcranial Magnetic Stimulation as a Treatment of Depression
More informationNoninvasive Neuromodulation Current State & Future Directions
Sarah H. Lisanby, MD Director, Translational Research Division Team B Lead BRAIN Initiative Chief, Noninvasive Neuromodulation Unit Noninvasive Neuromodulation Current State & Future Directions Experimental
More informationObjectives. APNA 27th Annual Conference Session 1021: October 9, Brain Stimulation Techniques. Rosedale, Ecklesdafer, Kormos, Freedland, Knapp 1
The Significant Promise of Therapeutic Neuromodulation: Implications for Psychiatric Mental (PMH) Health Nursing Mary Rosedale PhD, PMHNP BC Donna Ecklesdafer, MSN, RN Theresa Kormos, MSN, PMHCNS BC Michelle
More informationBrian A. Coffman, PhD
Brian A. Coffman, PhD Research Instructor Department of Psychiatry University of Pittsburgh School of Medicine UPMC Western Psychiatric Hospital Pittsburgh, PA Dr. Brian Coffman is a Research Instructor
More informationOscar G. Morales. MD Founding Director McLean Hospital TMS
Institute of Medicine of the National Academies Non-Invasive Neuromodulation of the Central Nervous System: A Workshop Washington, DC. March 2 and 3, 2015 Session IV: Reimbursement Oscar G. Morales. MD
More informationMedical Policy An Independent Licensee of the Blue Cross and Blue Shield Association
of Depression and Other Psychiatric Disorders Page 1 of 26 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: See also: Transcranial Magnetic Stimulation (TMS)
More informationNeuromodulation in Dravet Syndrome. Eric BJ Segal, MD Director of Pediatric Epilepsy Northeast Regional Epilepsy Group Hackensack, New Jersey
Neuromodulation in Dravet Syndrome Eric BJ Segal, MD Director of Pediatric Epilepsy Northeast Regional Epilepsy Group Hackensack, New Jersey What is neuromodulation? Seizures are caused by synchronized
More informationTMS: Full Board or Expedited?
TMS: Full Board or Expedited? Transcranial Magnetic Stimulation: - Neurostimulation or neuromodulation technique based on the principle of electro-magnetic induction of an electric field in the brain.
More informationAPNA 28th Annual Conference Session 1024: October 22, 2014
Therapeutic Neuromodulation: Implications for Psychiatric Mental Health (PMH) Nurses Mary Rosedale PhD, PMHNP BC Donna Ecklesdafer, MSN, BSN, RN Dawn Miller, BSN, RN Julie Ann Mulder MS, BSN, BS, RN BC
More informationAP PSYCH Unit 13.3 Biomedical Therapies
AP PSYCH Unit 13.3 Biomedical Therapies Prescribed medications or medical procedures that act directly on the patient s nervous system. Drugs that alter brain chemistry Affecting brain circuitry with electric
More informationPharmacy Prior Authorization GMH/SA and Non-Title 19/21 SMI Non-Formulary and Prior Authorization Guidelines
Non-Formulary Behavioral Health Medications ADHD medications for children under The patient must have a diagnosis for which the requested medication is: o Approved based on FDA indication and limits; OR
More informationPatient Education Brief. NeuroStar TMS Therapies
Patient Education Brief NeuroStar TMS Therapies Provided by Dr Terrence A. Boyadjis MD 790 E Market Street Suite 245 West Chester, PA 19382 610.738.9576 About Depression Depression is a serious medical
More informationSubject: Transcranial Magnetic Stimulation
01-93875-18 Original Effective Date: 06/15/02 Reviewed: 12/06/18 Revised: 12/15/18 Subject: Transcranial Magnetic Stimulation THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More informationSupplementary Online Content
Supplementary Online Content Redlich R, Opel N, Grotegerd D, et al. Prediction of individual response to electroconvulsive therapy via machine learning on structural magnetic resonance imaging data. JAMA
More informationThe Evidence Base for rtms Reimbursement
The Evidence Base for rtms Reimbursement Bradley N. Gaynes, MD, MPH Professor of Psychiatry Associate Chair of Research Training and Education Institute of Medicine Workshop March 3, 2015 What do we know,
More informationTranscranial magnetic stimulation for the treatment of major depression
Neuropsychiatric Disease and Treatment open access to scientific and medical research Open Access Full Text Article Review Transcranial magnetic stimulation for the treatment of major depression Philip
More informationSuicide Risk and Melancholic Features of Major Depressive Disorder: A Diagnostic Imperative
Suicide Risk and Melancholic Features of Major Depressive Disorder: A Diagnostic Imperative Robert I. Simon, M.D.* Suicide risk is increased in patients with Major Depressive Disorder with Melancholic
More information1. Introduction Overview Organization of Executive Summary
Executive Summary and Discussion of the Vagus Nerve Stimulation (VNS) Therapy Depression Indication Clinical Data (Updated to Include Information from Deficiency Letter Response) Prepared By: Richard L.
More informationTRANSCRANIAL MAGNETIC STIMULATION
MEDICAL POLICY TRANSCRANIAL MAGNETIC STIMULATION Policy Number: 2013T0536F Effective Date: December 1, 2013 Table of Contents COVERAGE RATIONALE... BACKGROUND... CLINICAL EVIDENCE... U.S. FOOD AND DRUG
More informationIntroduction to TMS Transcranial Magnetic Stimulation
Introduction to TMS Transcranial Magnetic Stimulation Lisa Koski, PhD, Clin Psy TMS Neurorehabilitation Lab Royal Victoria Hospital 2009-12-14 BIC Seminar, MNI Overview History, basic principles, instrumentation
More informationModulation of the Neural Circuitry Underlying Obsessive-Compulsive Disorder
BRAIN STIMULATION LABORATORY Modulation of the Neural Circuitry Underlying Obsessive-Compulsive Disorder OCD Awareness Day NOLAN WILLIAMS, M.D. Instructor Department of Psychiatry Stanford University October
More informationTranscranial Magnetic Stimulation:
Transcranial Magnetic Stimulation: What has experience told us? Jonathan Downar MD PhD FRCPC MRI-Guided rtms Clinic University Health Network www.rtmsclinic.ca Disclosures Research funding: Canadian Institutes
More informationΝευροφυσιολογία και Αισθήσεις
Biomedical Imaging & Applied Optics University of Cyprus Νευροφυσιολογία και Αισθήσεις Διάλεξη 19 Ψυχασθένειες (Mental Illness) Introduction Neurology Branch of medicine concerned with the diagnosis and
More informationDiagnosis & Management of Major Depression: A Review of What s Old and New. Cerrone Cohen, MD
Diagnosis & Management of Major Depression: A Review of What s Old and New Cerrone Cohen, MD Why You re Treating So Much Mental Health 59% of Psychiatrists Are Over the Age of 55 AAMC 2014 Physician specialty
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationClinical Use of Ketamine in Psychiatry
Clinical Use of Ketamine in Psychiatry C. Sophia Albott, MD, MA Assistant Professor Department of Psychiatry and Behavioral Sciences University of Minnesota Medical School November 17, 2018 Disclosure
More informationObjectives. Objectives. A practice review. 02-Nov-16 MAJOR DEPRESSIVE DISORDER: NEW DEVELOPMENTS AND PRACTICAL IMPLICATIONS
MAJOR DEPRESSIVE DISORDER: NEW DEVELOPMENTS AND PRACTICAL IMPLICATIONS Jon-Paul Khoo What is treatment resistance really? Database review 328 consecutive non-remitted MDD patients referred for private
More informationHCT Medical Policy. Transcranial Magnetic Stimulation (TMS) for Major Depression Policy # 121 Current Effective Date: 05/24/2016.
HCT Medical Policy Transcranial Magnetic Stimulation (TMS) for Major Depression Policy # 121 Current Effective Date: 05/24/2016 Medical Policies are developed by HealthyCT to assist in administering plan
More informationGuilt Suicidality. Depression Co-Occurs with Medical Illness The rate of major depression among those with medical illness is significant.
1-800-PSYCH If you are obsessive-compulsive, dial 1 repeatedly If you are paranoid-delusional, dial 2 and wait, your call is being traced If you are schizophrenic, a little voice will tell you what number
More informationPSYCHOPHARMACOLOGY BULLETIN: Vol. 42 No. 2 5
DEMITRACK_MWM_549.QXP 7/14/9 1:46 PM Page 5 ORIGINAL RESEARCH Key Words: major depression, treatment resistance, transcranial magnetic stimulation, TMS, antidepressant, efficacy, safety, randomized clinical
More informationThe Neurobiology of Mood Disorders
The Neurobiology of Mood Disorders J. John Mann, MD Professor of Psychiatry and Radiology Columbia University Chief, Department of Neuroscience, New York State Psychiatric Institute Mood Disorders are
More informationOutline. Understanding Placebo Response in Psychiatry: The Good, The Bad, and The Ugly. Definitions
Outline Understanding Placebo Response in Psychiatry: The Good, The Bad, and The Ugly Michael E. Thase, MD Professor of Psychiatry Perelman School of Medicine University of Pennsylvania and Philadelphia
More informationTRANSCRANIAL MAGNETIC STIMULATION: CLINICAL UPDATE FOR PSYCHIATRIC APPLICATIONS ANNA MAZUR, PH.D. OSU DEPT. OF PSYCHIATRY AND BEHAVIORAL SCIENCES
TRANSCRANIAL MAGNETIC STIMULATION: CLINICAL UPDATE FOR PSYCHIATRIC APPLICATIONS ANNA MAZUR, PH.D. OSU DEPT. OF PSYCHIATRY AND BEHAVIORAL SCIENCES FINANCIAL DISCLOSURE I have financial relationships to
More informationBright Nights: Understanding Depression
Bright Nights: Understanding Depression KEVIN SETHI, MD MARCH 18 TH, 2019 Objectives Features of Depression Facts and Myths Treatment Options Medications Neuromodulation Cognitive Behavioral Therapy Mindfulness
More informationNon-therapeutic and investigational uses of non-invasive brain stimulation
Non-therapeutic and investigational uses of non-invasive brain stimulation Robert Chen, MA, MBBChir, MSc, FRCPC Catherine Manson Chair in Movement Disorders Professor of Medicine (Neurology), University
More informationTreating treatment resistant depression
Treating treatment resistant depression These slides are the intellectual property of Ian Anderson and must not be reproduced Ian Anderson Neuroscience and Psychiatry Unit University of Manchester and
More informationResearch Perspectives in Clinical Neurophysiology
Research Perspectives in Clinical Neurophysiology A position paper of the EC-IFCN (European Chapter of the International Federation of Clinical Neurophysiology) representing ~ 8000 Clinical Neurophysiologists
More informationBiological treatments: Electroconvulsive Therapy, Transcranial Magnetic Stimulation, Light therapy
Biological treatments: Electroconvulsive Therapy, Transcranial Magnetic Stimulation, Light therapy Basic trainee talk 23 May 2007 ECT When is ECT used. Depression. Severe, melancholic. Resistant to treatment.
More informationHHS Public Access Author manuscript J Neuropsychiatry Clin Neurosci. Author manuscript; available in PMC 2017 September 11.
HHS Public Access Author manuscript Published in final edited form as: J Neuropsychiatry Clin Neurosci. 2017 ; 29(2): 179 182. doi:10.1176/appi.neuropsych.16100181. Initial Response to Transcranial Magnetic
More informationNeurosoft TMS. Transcranial Magnetic Stimulator DIAGNOSTICS REHABILITATION TREATMENT STIMULATION. of motor disorders after the stroke
Neurosoft TMS Transcranial Magnetic Stimulator DIAGNOSTICS REHABILITATION TREATMENT of corticospinal pathways pathology of motor disorders after the stroke of depression and Parkinson s disease STIMULATION
More informationNeurophysiology & EEG
Neurophysiology & EEG PG4 Core Curriculum Ian A. Cook, M.D. Associate Director, Laboratory of Brain, Behavior, & Pharmacology UCLA Department of Psychiatry & Biobehavioral Sciences Semel Institute for
More informationPractice Guideline for the Treatment of Patients With Major Depressive Disorder: American Psychiatric Association
Practice Guideline for the Treatment of Patients With Major Depressive Disorder: American Psychiatric Association Our clinical advisor adds updated advice on electroconvulsive therapy, transcranial magnetic
More informationre-emerging role The Recent developments have revived interest in brain stimulation for difficult-to-treat patients
The re-emerging role Recent developments have revived interest in brain stimulation for difficult-to-treat patients GOMAN MEDICAL ILLUSTRATIONS FOR CURRENT PSYCHIATRY of therapeutic Philip G. Janicak,
More informationGuidelines MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD) Guidelines CH Lim, B Baizury, on behalf of Development Group Clinical Practice Guidelines Management of Major Depressive Disorder A. Introduction Major depressive
More informationDisorders of the Brain Systems
PART III Disorders of the Brain Systems I. INTRODUCTION As was shown in Part II, the brain can be divided into systems. These brain systems consist of separate cortical and subcortical anatomical structures
More informationSuitable dose and duration of fluvoxamine administration to treat depression
PCN Psychiatric and Clinical Neurosciences 1323-13162003 Blackwell Science Pty Ltd 572April 2003 1098 Dose and duration of fluvoxamine S. Morishita and S. Arita 10.1046/j.1323-1316.2002.01098.x Original
More informationIntroduction. Brain Basics will introduce you to some of this science, such as:
Introduction Welcome. Brain Basics provides information on how the brain works, how mental illnesses are disorders of the brain, and ongoing research that helps us better understand and treat disorders.
More informationDrugs for Emotional and Mood Disorders Chapter 16
Drugs for Emotional and Mood Disorders Chapter 16 NCLEX-RN Review Question 1 Choices Please note Question #1 at the end of Ch 16 pg 202 & Key pg 805 answer is #4 1. Psychomotor symptoms 2. Tachycardia,
More information